Clinical trials in gynecological cancer

International Journal of Gynecological Cancer

Volumn 17, Issue 3, 2007, Pages 547-556

  Trimble, E L ^a   Davis, J ^b   Disaia, P ^b   Fujiwara, K ^b   Gaffney, D ^b   Kristensen, G ^b   Ledermann, J ^b   Pfisterer, J ^b   Quinn, M ^b   Reed, N ^b   Schoenfeldt, M ^b   Thigpen, J T ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NONE

Author keywords

Cervical cancer; Clinical trials; Endometrial cancer; GCIG; Gynecologic cancer; Ovarian cancer

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CISPLATIN; DOCETAXEL; DOXORUBICIN; ERLOTINIB; ERYTHROPOIETIN; FLUOROURACIL; GEMCITABINE; HEMOGLOBIN; IFOSFAMIDE; NAVELBINE; PACLITAXEL; PLATINUM; TAMOXIFEN; TAXANE DERIVATIVE; TIRAPAZAMINE; TOPOTECAN; WART VIRUS VACCINE;

CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER RISK; CANCER SCREENING; CANCER SURGERY; CANCER SURVIVAL; CARCINOSARCOMA; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; CYSTIC LYMPHANGIOMA; ENDOMETRIUM CANCER; FINANCIAL MANAGEMENT; GOVERNMENT; GOVERNMENT REGULATION; GYNECOLOGIC CANCER; HEALTH CARE QUALITY; HISTOLOGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOTHERAPY; LAPAROSCOPY; LEG EDEMA; MONOTHERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; OVARY CANCER; OXYGENATION; PATIENT EDUCATION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RECTUM CANCER; REVIEW; SOCIAL WELFARE; SURVIVAL TIME; UTERINE CERVIX CANCER; VERRUCA VULGARIS; VULVA CANCER; WART VIRUS;

CLINICAL TRIALS; ENDOMETRIAL NEOPLASMS; FEMALE; GENITAL NEOPLASMS, FEMALE; HUMANS; NEOPLASM METASTASIS; OVARIAN NEOPLASMS; PAPILLOMAVIRUS INFECTIONS; VULVAR NEOPLASMS;

EID: 34248395054     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1111/j.1525-1438.2007.00667.x     Document Type: Review

References (55)

1. Available at:http://ctep.cancer.gov/resources/gcig/index.html
2. Koutsky LA, Ault KA, Wheeler CM et al Proof of Principle Study Investigators. A controlled trial of a human papillomavirus type 16 vaccine [see comment] [Clinical Trial. Journal Article. Multicenter Study. Randomized Controlled Trial]. N Engl J Med 2002 347:1645 51.
3. Harper DM, Franco EL, Wheeler C et al. GlaxoSmithKline HPV Vaccine Study Group. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial [see comment]. [Clinical Trial. Clinical Trial, Phase II. Journal Article. Multicenter Study. Randomized Controlled Trial]. Lancet 2004 364:1757 65.
4. Amendola MA, Hricak H, Mitchell DG et al. Utilization of diagnostic studies in the pretreatment evaluation of invasive cervical cancer in the United States: results of intergroup protocol ACRIN 6651/GOG 183. J Clin Oncol 2005 23:7454 9.
5. Miller TR, Grigsby PW. Measurement of tumor volume by PET to evaluate prognosis in patients with advanced cervical cancer treated by radiation therapy. Int J Radiat Oncol Biol Phys 2002 53:353 9.
6. Pearcy R, Brundage M, Drouin P et al. Phase III trial comparing radical radiation therapy with and without cisplatin chemotherapy in patients with advanced squamous cell carcinoma of the cervix. J Clin Oncol 2002 20:966 72.
7. Grogan M, Thomas GM, Melamed I et al. The importance of hemoglobin levels during radiotherapy for carcinoma of the cervix. Cancer 1999 86:1528 36.
8. Henke M, Laszig R, Rube C et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 2003 362:1255 60.
9. Arcasoy MO et al. Erythropoietin and erythropoietin receptor expression in head and neck cancer: relationship to tumor hypoxia. Clin Cancer Res 2005 11:20 7.
10. Eifel PJ, Winter K, Morris M et al. Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: an update of radiation therapy oncology group trial (RTOG) 90-01. J Clin Oncol 2004 22:872 80.
11. Keys HM, Bundy BN, Stehman FB et al. Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage Ib cervical carcinoma. N Engl J Med 1999 340:1154 61.
12. Whitney CW, Sause W, Bundy BN et al. Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIb-IVa carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study. J Clin Oncol 1999 17:1339 48.
13. Benedetti Panici P, Greggi S, Scambia G et al. Long-term survival following neoadjuvant chemotherapy and radical surgery in locally advanced cervical cancer. Eur J Cancer 1998 3:341 6.
14. Benedetti Panici P, Greggi S, Baiocchi G et al. Neoadjuvant chemotherapy and radical surgery in locally advanced cervical cancer. Cancer 1991 67:372 9.
15. Benedetti-Panici P, Greggi S, Colombo A et al. Neoadjuvant chemotherapy and radical surgery versus exclusive radiotherapy in locally advanced squamous cell cervical cancer. Results from the Italian multicenter randomized trial. J Clin Oncol 2002 20:179 88.
16. Tierney JF, Stewart LA, Parmar MK. Can the published data tell us about the effectiveness of neoadjuvant chemotherapy for locally advanced cancer of the uterine cervix? Eur J Cancer 1999 35:406 9.
17. Souhami L, Gil RA, Allan SE et al. A randomized trial of chemotherapy followed by pelvic radiation therapy in stage IIIB carcinoma of the cervix. J Clin Oncol 1991 9:970 7.
18. Tattersall MH, Lorvidhaya V, Vootiprux V et al. Randomized trial of epirubicin and cisplatin chemotherapy followed by pelvic radiation in locally advanced cervical cancer. Cervical Cancer Study Group of the Asian Oceanian Clinical Oncology Association. J Clin Oncol 1995 13:444 51.
19. Moore DH, Thomas GM, Montana GM, Saxer A, Gallup DG, Olt G. Preoperative chemoradiation for advanced vulvar cancer: a phase II study of the Gynecologic Oncology Group. Int J Radiat Oncol Biol Phys 1998 42:79 85.
20. Levenback C, Burke TW, Gershenson DM, Morris M, Malpica A, Ross MI. Intraoperative lymphatic mapping for vulvar cancer. Obstet Gynecol 1994 84:163 7.
21. De Hullu JA, Hollema H, Piers DA et al. Sentinel lymph node procedure is highly accurate in squamous cell carcinoma of the vulva. J Clin Oncol 2000 18:2811 6.
22. Creutzberg CL, van Putten WLJ, Koper PC et al. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-I endometrial carcinoma Multicentre randomised trial. PORTEC Study Group. Post-Operative Radiation Therapy in Endometrial Carcinoma. Lancet 2000 355:1404 11.
23. Keys HM, Roberts AJ, Brunetto VL et al. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2004 92:744 51.
24. Vergote I, Kjorstad K, Abeler V et al. A randomized trial of adjuvant progestagen in early endometrial cancer. Cancer 1989 64:1011 5.
25. COSA-NZ-UK Endometrial Cancer Study Groups. Adjuvant medroxyprogesterone acetate in high-risk endometrial cancer. Int J Gynecol Cancer 1998 8:387 91.
26. Randall ME, Brunetto G, Muss H et al. Whole abdominal radiotherapy versus combination doxorubicin-cisplatin chemotherapy in advanced endometrial carcinoma: a randomized phase III trial of the Gynecologic Oncology Group [abstract]. Proc Am Soc Clin Oncol 2003 22:2. Abstract 3.
27. Fleming GF, Brunetto VL, Cella D et al. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol 2004 22:2159 66.
28. Sugiyama T, Kamura T, Kigawa J et al. Clinical characteristics of clear cell carcinoma of the ovary. Cancer 2000 88:2584 9.
29. Takano M, Kita T, Kikuchi Y et al. Clinical characteristics of clear cell adenocarcinoma of the ovary - Japan Clear Cell Carcinoma Study Group [abstract]. Proc Am Soc Clin Oncol 2005 23:484s. Abstract 5123.
30. Enomoto T, Kuragaki C, Yamasaki M et al. Is clear cell carcinoma and mucinous carcinoma of the ovary sensitive to combination chemotherapy with paclitaxel and carboplatin? [abstract]. Proc Am Soc Clin Oncol 2003 22:447. Abstract 1797.
31. Andriole GL, Reding D, Hayes RB, Prorok PC, Gohagan JK. The prostate, lung, colon, and ovarian (PLCO) cancer screening trial: status and promise. Urol Oncol (Seminars and Original Investigations) 2004 22:358 61.
32. Available at:www.ukctocs.org.uk/
33. Zhang Z, Bast RC Jr., Yu Y et al. Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res 2004 64:5882 90.
34. Trimbos JB, Vergote I, Bolis G et al. Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial. J Natl Cancer Inst 2003 95:113 25.
35. Young RC, Decker DG, Wharton JT, Piver MS, Sindelar WF, Edwards BK. Staging laparotomy in early ovarian cancer. JAMA 1983 250:3072 6.
36. Young RC, Brady MF, Nieberg RK et al. Adjuvant treatment for early ovarian cancer: a randomized phase III trial of intraperitoneal 32P or intravenous cyclophosphamide and cisplatin - a Gynecologic Oncology Group study. J Clin Oncol 2003 21:4350 5.
37. Trope C, Kaern J, Hogberg T et al. Randomized study on adjuvant chemotherapy in stage I high-risk ovarian cancer with evaluation of DNA-ploidy as prognostic instrument. Ann Oncol 2000 11:281 8.
38. Vasey PA, Jayson GC, Gordon A et al. Scottish Gynaecological Cancer Trials Group. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. [Clinical Trial. Clinical Trial, Phase III. Journal Article. Multicenter Study. Randomized Controlled Trial]. J Natl Cancer Inst 2004 96:1682 91.
39. Ledermann JA, Frickhofen N, Wandt H et al. A phase III randomized trial of sequential high dose chemotherapy with peripheral blood stem cell support or standard dose chemotherapy for first-line treatment of ovarian cancer [abstract]. Proc Am Soc Clin Oncol 2005 23:456s. Abstract 5006.
40. Alberts DS, Liu PY, Hanningan EV et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 1996 335:1950 5.
41. Markman M, Bundy BN, Alberts DS et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an Intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol 2001 19:1001 7.
42. Armstrong D, Bundy BN, Wenzel L et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 2006 354:34 43.
43. Available at:www.cancer.gov/clinicaltrials/developments/IPchemo-digest
44. Vergote I, Piccart M, Scarfone G et al. Randomized phase III EORTC-GCG study comparing intraperitoneal (ip) cisplatin (P) versus observation in ovarian cancer (O.C.) patients (pts) with a pathologically complete remission (pCR) after first-line chemotherapy. Proceedings from the 2004 annual meeting of the Society of Gynecologic Oncologists.
45. Parmar MK, Ledermann JA, Colombo N et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 2003 361:2099 106.
46. Pfisterer J, Plante M, Vergote I et al. Gemcitabine/carboplatin (GC) vs. carboplatin (C) in platinum sensitive recurrent ovarian cancer (OVCA). Results of a Gynecologic Cancer Intergroup randomised phase III trial of the AGO OVAR, the NCIC CTG and the EORTC [abstract]. J Clin Oncol 2004 22. Abstract 5005.
47. Available at:www.cancer.gov/clinicaltrials
48. Available at:www.thelancet.com
49. Available at:http://ctep.cancer.gov/guidelines/
50. Available at:http://www.nice.org.uk/
51. Munoz KA, Harlan LC, Trimble EL. Patterns of care for women with ovarian cancer in the United States. J Clin Oncol 1997 15:3408 15.
52. Harlan LC, Clegg LX, Trimble EL. Trends in surgery and chemotherapy for women diagnosed with ovarian cancer in the United States. J Clin Oncol 2003 21:3488 94.
53. Trimble EL, Harlan LC, Clegg LX, Cornelison T. Untreated cervical cancer in the United States. Gynecol Oncol 2005 96:271 7.
54. Emanuel EJ, Schnipper LE, Kamin DY et al. The costs of conducting clinical research. J Clin Oncol 2003 21:4145 50.
55. Available at:http://www.wma.net/e/policy/b3.htm